Peptide Therapy: What You Need to Know Before Starting

Peptide therapy refers to the medical use of peptides — short chains of amino acids — to influence specific biological processes in the body. Unlike conventional pharmaceutical drugs that are typically synthetic small molecules, therapeutic peptides mimic natural signaling molecules that the body already produces.

The field spans two distinct categories. First, there are FDA-approved peptide drugs like semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and bremelanotide (Vyleesi). These have gone through rigorous clinical trials, have established safety profiles, and are prescribed through conventional medical channels. Second, there are compounded peptides — compounds like BPC-157, CJC-1295, ipamorelin, and thymosin alpha-1 that are prepared by compounding pharmacies and prescribed off-label by physicians. These have varying levels of evidence and have not been through the FDA approval process.

Understanding this distinction is critical. When someone says "peptide therapy," they could mean either category, and the evidence base, regulatory status, and safety profiles are fundamentally different.

Peptide therapy is typically prescribed by physicians in integrative medicine, functional medicine, anti-aging medicine, sports medicine, or endocrinology. The prescribing landscape varies significantly by peptide type.

FDA-approved peptides (semaglutide, tirzepatide) can be prescribed by any licensed physician, including primary care doctors, endocrinologists, and obesity medicine specialists. These are available at standard pharmacies and increasingly through telehealth platforms.

Compounded peptides (BPC-157, CJC-1295, ipamorelin, etc.) are typically prescribed by physicians with specific training in peptide protocols. These practitioners often hold certifications from organizations like the American Academy of Anti-Aging Medicine (A4M) or the Institute for Functional Medicine (IFM).

What to look for in a provider: Board certification in their primary specialty. Experience with the specific peptides you are considering. Willingness to discuss both benefits and limitations of the evidence. A structured monitoring protocol with baseline and follow-up lab work. Transparency about costs and what insurance does and does not cover. Red flags include providers who guarantee results, dismiss risks, or recommend peptides without a thorough medical evaluation.

Cost is one of the most important practical considerations for patients. The range varies dramatically depending on the peptide and the provider model.

FDA-approved GLP-1 drugs: List price for semaglutide and tirzepatide has been approximately $1,000-1,300 per month, though Novo Nordisk announced a 70% price reduction in 2026. Insurance coverage varies — many plans now cover these drugs for obesity or type 2 diabetes indications. Compounded versions are available for $159-400 per month.

Compounded peptides (general range): - BPC-157: $100-250 per month - CJC-1295 + Ipamorelin stack: $250-450 per month - TB-500: $150-300 per month - Thymosin Alpha-1: $200-400 per month - GHK-Cu: $100-200 per month

Additional costs to factor in: - Initial consultation: $200-500 (often not covered by insurance) - Follow-up visits: $100-300 every 4-8 weeks - Lab work: $200-600 for baseline panels, $100-300 for follow-ups - Supplies (syringes, alcohol swabs, sharps container): $20-40 per month

Insurance reality: Compounded peptides are almost never covered by insurance. FDA-approved peptide drugs have variable coverage. Many peptide therapy practices operate on cash-pay or concierge models. Total annual cost for compounded peptide therapy typically ranges from $3,000-8,000 including provider visits and lab work.

Peptide therapy protocols vary by compound, indication, and provider philosophy. Here are the most common therapeutic applications:

Tissue repair and recovery. BPC-157 and TB-500 are the most commonly prescribed healing peptides. Typical protocols involve subcutaneous injection near the injury site or systemically for 4-12 weeks. These are popular among patients recovering from sports injuries, tendon damage, and gut issues. Evidence level: Preliminary (extensive animal data, very limited human data).

Growth hormone optimization. CJC-1295 combined with ipamorelin is the most popular growth hormone secretagogue stack. These peptides stimulate natural GH release rather than providing exogenous growth hormone. Typical protocols run 8-16 weeks with periodic breaks. Common goals include improved body composition, sleep quality, and recovery. Evidence level: Preliminary to Moderate.

Weight management. Semaglutide and tirzepatide are the evidence leaders here, with robust Phase 3 clinical trial data showing 15-25% body weight reduction. These are FDA-approved and represent the gold standard of peptide therapy evidence. Evidence level: Strong.

Immune support. Thymosin alpha-1 is prescribed for immune modulation, particularly in immunocompromised patients. It has been approved in multiple countries outside the US for hepatitis B and as an immune adjuvant. Evidence level: Moderate.

Cognitive enhancement. Selank and semax are prescribed for cognitive function, anxiety, and mood. Both have regulatory approval in Russia and some clinical data. Evidence level: Moderate (with geographic limitations on the research).

Setting realistic expectations is essential. Peptide therapy is not a miracle cure, and outcomes vary significantly between individuals.

First 2-4 weeks. For most compounded peptides, noticeable effects take time. Some patients report improved sleep quality within the first week of GH secretagogues. BPC-157 users sometimes notice reduced pain or inflammation within 1-2 weeks. GLP-1 drugs typically begin appetite suppression within the first week.

Weeks 4-8. This is when most patients begin to notice meaningful changes. Body composition shifts from GH peptides, continued healing progress from tissue repair peptides, and 5-8% body weight reduction from GLP-1 agonists.

Weeks 8-16. Full protocol duration for most compounded peptides. Results should be evaluated against baseline measurements and lab work. If no meaningful improvement is observed by week 12, the protocol should be reassessed.

Honest assessment of outcomes. The most common patient complaint about peptide therapy is that results are more subtle than expected. Social media creates unrealistic expectations. In reality, compounded peptide effects are typically modest and gradual — improvements in sleep, recovery, energy, and body composition measured in percentages, not dramatic transformations. FDA-approved GLP-1 drugs produce more dramatic, measurable results because they have been optimized through clinical development.

Responsible peptide therapy requires ongoing medical monitoring. Patients should expect and demand the following:

Baseline labs before starting: Complete blood count, comprehensive metabolic panel, fasting insulin and glucose, IGF-1 (for GH peptides), thyroid panel, inflammatory markers (CRP, ESR), and any condition-specific labs relevant to the treatment goals.

Ongoing monitoring: Follow-up labs every 8-12 weeks during active treatment. IGF-1 levels should be monitored for GH secretagogues to ensure levels remain in a safe range. HbA1c for patients on GLP-1 therapy. Liver and kidney function should be checked periodically.

Side effects to watch for: - GH secretagogues: Water retention, joint stiffness, increased hunger, tingling/numbness (carpal tunnel-like symptoms) - BPC-157: Generally well tolerated; occasional nausea, dizziness - GLP-1 drugs: Nausea (most common, usually transient), constipation, diarrhea, pancreatitis (rare) - TB-500: Headache, localized injection site reactions

When to stop. Any unexplained adverse symptoms should prompt immediate consultation with your prescriber. Persistent headaches, vision changes, significant joint swelling, or signs of allergic reaction warrant stopping the peptide and seeking medical evaluation.

The self-administration reality. Many patients self-inject at home after initial training. This is acceptable for subcutaneous injections with proper training and sterile technique, but the prescribing physician remains responsible for monitoring and should be accessible for questions.